GW starts Phase III in cancer pain

GW Pharmaceuticals (LSE:GWP) began a double-blind, placebo-controlled Phase III trial of its sublingual cannabis spray to treat pain that is not responding to standard treatment in more than 100 cancer patients in the U.K. The product also is in Phase III testing for multiple sclerosis (MS) and brachial plexus injury (nerve-damage pain). ...